CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue:
Total revenue	$ 24,144	$ 23,625	$ 66,237	$ 70,032
Operating costs and expenses:
Cost of goods sold	12,431	4,972	26,485	15,402
Research and development	24,070	33,590	84,220	183,583
General and administrative	21,147	22,534	60,097	70,394
Restructuring, impairment and costs of terminated program	11,360	16,830	49,107	124,350
Impairment of goodwill	0	0	76,501	0
Total operating costs and expenses	69,008	77,926	296,410	393,729
Loss from operations	(44,864)	(54,301)	(230,173)	(323,697)
Non-operating income (expense):
Change in fair value of development derivative liability	0	0	0	33,427
Non-cash interest expense on liabilities related to the sales of future royalties	(5,910)	(6,953)	(18,467)	(21,710)
Interest income and other income (expense), net	4,876	2,050	14,492	3,541
Total non-operating income (expense), net	(1,034)	(4,903)	(3,975)	15,258
Loss before provision for income taxes	(45,898)	(59,204)	(234,148)	(308,439)
Provision (benefit) for income taxes	(61)	(155)	(171)	71
Net loss	$ (45,837)	$ (59,049)	$ (233,977)	$ (308,510)
Basic net loss per share (in dollars per share)	$ (0.24)	$ (0.31)	$ (1.23)	$ (1.65)
Diluted net loss per share (in dollars per share)	$ (0.24)	$ (0.31)	$ (1.23)	$ (1.65)
Weighted average shares outstanding used in computing basic net loss per share (in shares)	190,406	187,641	189,651	186,767
Weighted average shares outstanding used in computing diluted net loss per share (in shares)	190,406	187,641	189,651	186,767
Product sales
Revenue:
Total revenue	$ 5,822	$ 4,969	$ 15,198	$ 15,969
Non-cash royalty revenue related to the sales of future royalties
Revenue:
Total revenue	18,167	18,342	50,860	52,167
License, collaboration and other revenue
Revenue:
Total revenue	$ 155	$ 314	$ 179	$ 1,896